[go: up one dir, main page]

MX2021006326A - Inhibidores de pcna. - Google Patents

Inhibidores de pcna.

Info

Publication number
MX2021006326A
MX2021006326A MX2021006326A MX2021006326A MX2021006326A MX 2021006326 A MX2021006326 A MX 2021006326A MX 2021006326 A MX2021006326 A MX 2021006326A MX 2021006326 A MX2021006326 A MX 2021006326A MX 2021006326 A MX2021006326 A MX 2021006326A
Authority
MX
Mexico
Prior art keywords
pcna
inhibitors
pcna inhibitors
modulators
compositions
Prior art date
Application number
MX2021006326A
Other languages
English (en)
Inventor
David Horne
Long Gu
Linda H Malkas
Robert J Hickey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58289682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021006326(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of MX2021006326A publication Critical patent/MX2021006326A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

En la presente, se describen, entre otras cosas, composiciones de moduladores de PCNA y métodos para tratar o prevenir el cáncer.
MX2021006326A 2015-09-17 2016-09-16 Inhibidores de pcna. MX2021006326A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562220014P 2015-09-17 2015-09-17
US201662313592P 2016-03-25 2016-03-25
US201662340964P 2016-05-24 2016-05-24
PCT/US2016/052310 WO2017049206A1 (en) 2015-09-17 2016-09-16 Pcna inhibitors

Publications (1)

Publication Number Publication Date
MX2021006326A true MX2021006326A (es) 2022-12-16

Family

ID=58289682

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003301A MX382996B (es) 2015-09-17 2016-09-16 Inhibidores de pcna
MX2021006326A MX2021006326A (es) 2015-09-17 2016-09-16 Inhibidores de pcna.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018003301A MX382996B (es) 2015-09-17 2016-09-16 Inhibidores de pcna

Country Status (10)

Country Link
US (5) US10550070B2 (es)
EP (2) EP3349754B1 (es)
JP (4) JP6966996B2 (es)
KR (2) KR102768838B1 (es)
CN (2) CN108348512B (es)
AU (3) AU2016324158B2 (es)
CA (1) CA2999080C (es)
IL (4) IL282400B (es)
MX (2) MX382996B (es)
WO (1) WO2017049206A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10420840B2 (en) * 2015-04-10 2019-09-24 Rll, Llc Anticancer therapeutic agents
IL282400B (en) 2015-09-17 2022-08-01 Hope City Pcna inhibitors
US11392971B1 (en) * 2017-12-29 2022-07-19 Groupon, Inc. Methods and systems for generating a supply index indicative of a quality of available supply of merchant promotions
US11551247B1 (en) 2017-12-29 2023-01-10 Groupon, Inc. Methods and systems for determining a travel propensity configured for use in the generation of a supply index indicative of a quality of available supply
CN117460714A (zh) * 2021-04-30 2024-01-26 希望之城 用于癌症治疗的pcna抑制剂和egfr抑制剂
AU2023231620A1 (en) * 2022-03-07 2024-09-12 City Of Hope Pcna inhibitors and uses thereof
WO2025054318A1 (en) * 2023-09-06 2025-03-13 City Of Hope Pcna inhibitors and uses thereof
CN117603081A (zh) * 2023-11-28 2024-02-27 沈阳药科大学 N-(2-((2-(3-甲氧基苯氧基)苯基)氨基)-2-乙酰氧基)-1-萘胺的制备方法
CN120097860A (zh) * 2023-12-05 2025-06-06 杜心赟 增殖细胞核抗原抑制剂、其制备方法、其中间体、其药物组合物和用途
WO2025184571A1 (en) * 2024-03-01 2025-09-04 City Of Hope Pcna inhibitors for the treatment of myc family associated cancers
CN118546074B (zh) * 2024-05-27 2025-06-06 安徽贝克制药股份有限公司 一种氘代增殖细胞核抗原抑制剂及其制备方法和其应用
CN118459363B (zh) * 2024-05-27 2024-12-17 安徽贝克制药股份有限公司 一种氟取代增殖细胞核抗原抑制剂及其制备方法和其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1295611A (en) * 1916-07-29 1919-02-25 Moritz D Schwartz Metatarsal support.
US1298989A (en) * 1918-11-14 1919-04-01 Reed Foundry & Machine Co Tractor-plow.
US4030910A (en) 1974-01-22 1977-06-21 The Dow Chemical Company Substituted pyridinyloxy(thio)phenyl -acetamides, -ureas and urea derivatives, herbicidal compositions and methods containing same
US4269829A (en) 1979-06-18 1981-05-26 Rohm And Haas Company Method and composition for treating helminths containing O,O-dialkyl-N-(substituted phenyl)aminothiocarbonyl phosphoramidates
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
FR2723739B1 (fr) * 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
US5783597A (en) 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US6258822B1 (en) 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
WO1999047545A2 (en) 1998-03-19 1999-09-23 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
WO1999048859A1 (en) 1998-03-20 1999-09-30 Bristol-Myers Squibb Company Aryloxyanilides and related compounds
TWI282785B (en) 2000-05-30 2007-06-21 Chugai Pharmaceutical Co Ltd A compound having thrombopoietin-like activities
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
GB0319126D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
CA2542064A1 (en) 2003-10-24 2005-05-06 Exelixis, Inc. Tao kinase modulators and methods of use
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20070155727A1 (en) * 2005-12-29 2007-07-05 Schering Aktiengessellschaft Amide inhibitors of leukotriene A4 hydrolase
US8791102B2 (en) * 2008-10-17 2014-07-29 Exelixis, Inc. Acetanilide sphingosine-1-phosphate receptor antagonists
EP2349252A2 (en) 2008-10-17 2011-08-03 Exelixis, Inc. Synergistic combination of sphingosine-1-phosphate receptor antagonists and antimicrotubule agents
GB201011411D0 (en) 2010-07-06 2010-08-18 St Georges Hosp Medical School Therapeutic compounds and their use
JP5985473B2 (ja) * 2010-07-13 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
US8710039B2 (en) 2010-11-01 2014-04-29 The Penn State Research Foundation Therapeutic compositions and methods
US20130345231A1 (en) * 2011-03-23 2013-12-26 Indiana University Research And Technology Corporation Anticancer therapeutic agents
EP3112343B1 (en) * 2014-02-28 2023-03-29 Tohoku University Amide derivatives
IL282400B (en) * 2015-09-17 2022-08-01 Hope City Pcna inhibitors

Also Published As

Publication number Publication date
EP3349754A4 (en) 2019-03-20
IL258174A (en) 2018-05-31
HK1258793A1 (en) 2019-11-22
WO2017049206A1 (en) 2017-03-23
US10550070B2 (en) 2020-02-04
IL276115B (en) 2021-05-31
US20240343682A1 (en) 2024-10-17
IL294381B2 (en) 2023-07-01
BR112018005331A2 (pt) 2018-10-09
EP3349754A1 (en) 2018-07-25
AU2016324158A1 (en) 2018-04-12
JP2025128193A (ja) 2025-09-02
EP4616910A2 (en) 2025-09-17
US20220340516A1 (en) 2022-10-27
KR20180069817A (ko) 2018-06-25
IL282400B (en) 2022-08-01
US12054447B2 (en) 2024-08-06
US12435030B2 (en) 2025-10-07
CN108348512B (zh) 2021-09-03
JP7690553B2 (ja) 2025-06-10
JP2022028665A (ja) 2022-02-16
CA2999080C (en) 2023-11-14
MX2018003301A (es) 2019-02-07
JP2019500315A (ja) 2019-01-10
AU2020270487B2 (en) 2022-12-15
AU2020270487A1 (en) 2020-12-17
KR20250026875A (ko) 2025-02-25
JP7399925B2 (ja) 2023-12-18
IL276115A (en) 2020-08-31
AU2023201501B2 (en) 2024-07-04
AU2016324158B2 (en) 2020-08-27
CN113620833A (zh) 2021-11-09
KR102768838B1 (ko) 2025-02-14
US10913706B2 (en) 2021-02-09
IL282400A (en) 2021-06-30
EP3349754B1 (en) 2025-07-16
MX382996B (es) 2025-03-13
US11345656B2 (en) 2022-05-31
US20180339960A1 (en) 2018-11-29
CA2999080A1 (en) 2017-03-23
AU2023201501A1 (en) 2023-04-13
US20210078938A1 (en) 2021-03-18
JP2024028846A (ja) 2024-03-05
IL294381B1 (en) 2023-03-01
CN108348512A (zh) 2018-07-31
JP6966996B2 (ja) 2021-11-17
IL258174B (en) 2020-08-31
NZ740817A (en) 2024-03-22
IL294381A (en) 2022-08-01
US20200216386A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
MX2021006326A (es) Inhibidores de pcna.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
PH12017501999A1 (en) K-ras modulators
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
GB2541571A (en) Pharmaceutical compositions
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2019005833A (es) Administracion transdermica de agentes grandes.
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
PH12017501879A1 (en) Methods for treating cancer
PH12017501864A1 (en) Compositions and methods for treating autism
MX390320B (es) Farmaco de combinacion.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
PH12017500602A1 (en) Methods for treating ocular conditions